retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity First-in-Class 'Triple-G'! Retatrutide, a first-in-class GIP, & hormone receptor drug leads to nearly 29% weight loss in first pivotal test! Eli Lilly announced positive topline results from the Retatrutide: How Triple GLP-1/GIP/Glucagon Receptor

The demand is perpendicular to rising obesity and diabetes cases, with the 2025 World Obesity Atlas projecting that the total number of adults living with obesity will increase by around 115 percent by 2030

Blood in urine : Hematuria always requires investigation to exclude infection, kidney stones, or more serious urological conditions

If you are new to subcutaneous injections entirely, the beginner peptide injection guide covers fundamentals like needle selection, air bubble removal, and anxiety management

With submissions filed throughout early 2026, summer approvals would align with the regulatory agency's standard processing schedule

Most users experience bloating, gas, or temporary digestive changes during the initial adjustment period